共 8 条
[3]
临床药理学[M]. - 人民卫生出版社 , 李家泰主编, 1998
[4]
PD-160 The relationship between epidermal growth factor receptor (EGFR) mutations and clinicopathologic features in non-small cell lung cancers[J] . M. Tukumo,S. Toyooka,K. Kiura,H. Shigematsu,H. Asano,M. Aoe,M. Tanimoto,H. Date,A. Gazdar,N. Shimizu.Lung Cancer . 2005
[5]
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence .2 Mitsudomi T,Kosaka T,Endoh H,Horio Y,Hida T,Mori S,Hatooka S,Shinoda M,Takahashi T,Yatabe Y. J Clin Oncol . 2005
[6]
Skin rash and good performance status predict i mproved survival with gefitinib in pa-tients with advanced non-small cell lung cancer .2 Mohamed MK,Ramalingam S,Lin Y,et al. Ann Oncol . 2005
[7]
For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer .2 Schiller JH,Harrington D,Belani CP,et al. N Engl J Med . 2002
[8]
Phase I safety,phar-macokinetic,and pharmacodynamic trial of ZD1839,a se-lective oral epidermal growth factor receptor tyrosine kinaseinhibitor in patients with five selected solid tumor types〔J〕 .2 Baselga I,Rischin D,Ranson M,et al. Clin Oncol . 2002